The role of PET radiomic features in prostate cancer: a systematic review

ConclusionTo date, although PET literature appears still too narrow to draw definitive conclusions, PET-derived RFs appear promising in PCa. ML seems an important tool that may contribute to the widespread use of radiomics and subsequent implementation in the clinical setting.
Source: Clinical and Translational Imaging - Category: Radiology Source Type: research

Related Links:

In conclusion, a solitary thickened extraocular eye muscle should be recognized in time and examined further.Case Rep Ophthalmol 2021;12:870 –874
Source: Case Reports in Ophthalmology - Category: Opthalmology Source Type: research
Clin Nucl Med. 2021 Oct 21. doi: 10.1097/RLU.0000000000003954. Online ahead of print.ABSTRACT68Ga-labeled prostate-specific membrane antigen (PSMA)-11 PET/CT has evolved as the noninvasive imaging modality of choice in prostatic adenocarcinoma to detect overexpression of PSMA on prostate cancer cells. Metastasis to the thyroid gland is rarely observed in clinical practice of prostatic adenocarcinoma. Herein, we report the first and rare case of metastatic castration-resistant prostatic adenocarcinoma with thyroid metastasis. The patient demonstrated intensely PSMA-expressing primary prostatic lesion, metastatic lymph nodes...
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Source Type: research
In this study, we analyzed 10 years' worth of data from the nationwide database to determine the rates of coexisting malignancies and second primary cancers associated with uveal melanoma. The mean annual incidence of uveal melanoma was 1.1 per million. Approximately 43% of patients had coexisting cancers. The most common coexisting cancer was lung cancer (10%) followed by liver cancer (6%) and non-Hodgkin lymphoma (6%). In patients whose first cancer in their lifetime was uveal melanoma, the 10-year cumulative incidence of second primary cancers was 22% (95% confidence interval, 9-31%). The age- and sex-adjusted standard ...
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Source Type: research
Claudia E. Rübe Carl Mann H2A.J is a poorly studied mammalian-specific variant of histone H2A. We used immunohistochemistry to study its localization in various human and mouse tissues. H2A.J showed cell-type specific expression with a striking enrichment in luminal epithelial cells of multiple glands including those of breast, prostate, pancreas, thyroid, stomach, and salivary glands. H2A.J was also highly expressed in many carcinoma cell lines and in particular, those derived from luminal breast and prostate cancer. H2A.J thus appears to be a novel marker for luminal epithelial cancers. Knocking-out the H2AFJ ...
Source: Genes - Category: Genetics & Stem Cells Authors: Tags: Article Source Type: research
Oncology (Williston Park). 2021 Oct 19;35(9):620-627. doi: 10.46883/ONC.2021.3510.0620.ABSTRACTObjectives: This work aims to evaluatecomprehensive geriatric assessment (CGA) tools to better guide patients with urogenital carcinomas perioperatively and, consequently, to intensify or reduce hospital resource use. Methods: After informed consent, 111patients were included, all aged more than 65 years, with oncological surgery (with proof of a malignancy), a Mini Mental State Examination (MMSE) score of at least 23 points, and a prospective life expectancy of more than 2 months. Patients were divided into 2 groups: prostate ca...
Source: Oncology (Williston Park, N.Y.) - Category: Cancer & Oncology Authors: Source Type: research
Cabozantinib (XL-184) is a multitarget tyrosine kinase inhibitor (TKI) targeting receptor tyrosine kinases (RTKs) involved in oncogenesis and angiogenesis. It is currently the standard therapy for medullary thyroid cancer (MTC), metastatic renal cell carcinoma (mRCC), and hepatocellular carcinoma (HCC). Combination of Cabozantinib with immunotherapy is now a standard treatment in metastatic renal cancer, and its efficacy is being tested in ongoing clinical trial in prostate cancer patients. Here, we report that Cabozantinib may exert an immunostimulatory role by inducing immunogenic stress of prostate cancer cells and dire...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSION: lncRNA FGF14-AS2 was a downregulated lncRNA in prostate carcinoma and influenced cell proliferation and metastasis. The influence relied on modulating miR-96-5p and its target gene AJAP1.PMID:34655124 | DOI:10.1002/jcla.24012
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Source Type: research
In conclusion, compounds5a and6e are novel GRPR antagonists with potent anticancer activity.
Source: Medicinal Chemistry Research - Category: Chemistry Source Type: research
CONCLUSIONS: Urological malignancies are not common in heart and lung transplant recipients; however, standard management options can be safely used, including radical surgery. Prospective monitoring of these patients and potential considerations for screening should be maintained.PMID:34641776 | DOI:10.6002/ect.2021.0206
Source: Experimental and Clinical Transplantation : official journal of the Middle East Society for Organ Transplantation - Category: Transplant Surgery Authors: Source Type: research
Clin Transl Oncol. 2021 Oct 13. doi: 10.1007/s12094-021-02715-5. Online ahead of print.ABSTRACTNew clinical evidence suggests that dysregulation of the ubiquitin-mediated destruction of tumor suppressors or oncogene products is probably engaged in the etiology of leukemia and carcinoma. The superfamily of tripartite motif (TRIM)-containing protein family is among the biggest recognized single protein RING finger E3 ubiquitin ligases that are considered vital carcinogenesis regulators, which is not shocking since TRIM proteins are engaged in various biological processes, including cell growth, development, and differentiati...
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Databases & Libraries | Learning | Prostate Cancer | Radiology | Study | Universities & Medical Training